PRESS RELEASE: Seven High-Profile Patient Engagement Leaders to Advise Nonprofit on its Patient-Focused Research Agenda

Alexandria, VA – May 6, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of value assessment, today announced the appointment of seven members to its Patient Advisory Council, and advisory body designed to ensure the patient always remains at the forefront of value assessment. The Council, which [...]

2020-05-06T12:17:47-06:00May 6th, 2020|IVI News, Press|

PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs

Participants Define Consensus Expectations and Prioritize Research Agenda to Improve Value Assessment Methods Alexandria, VA – March 17, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of value assessment, recently hosted a first-of-its-kind multi-stakeholder summit to examine current gaps and emerging approaches in value assessment. The program [...]

2020-03-20T11:51:10-06:00March 17th, 2020|IVI News, Press|

The Ascendency of Value Assessment

Value assessment is a hot topic in healthcare. But how can it be improved so it's more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains why we need data partners to catalyze improvement in value assessment. Read the article here.

2020-02-26T16:33:39-06:00February 7th, 2020|IVI News, Viewpoints|

PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer

IVI is thrilled to announce Pat Deverka, MD has joined our organization as our first Chief Science Officer. Dr. Deverka. Dr. Deverka brings to IVI more than three decades of experience in health economic research, public policy, patient engagement and program measurement across several academic, corporate and non-profit institutions. Read the full press release [...]

2020-02-03T12:45:09-06:00February 4th, 2020|IVI News, Press|

What’s in Store for 2020?

Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip [...]

2020-02-26T16:39:47-06:00January 9th, 2020|IVI News, Viewpoints|

IVI Unveils Updates to Rheumatoid Arthritis Model

The Center for Biosimilars writes about IVI's recent updates to their IVI-RA value model to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized control trial (RCT) evidence, and updated cost estimates. Read the full article here.

2020-02-26T16:42:58-06:00January 8th, 2020|IVI News|

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

2020-01-07T00:30:08-06:00January 7th, 2020|IVI News, Press|